Clearside Biomedical, Inc. has announced the presentation of two subgroup analyses from its ODYSSEY Phase 2b clinical trial at the Angiogenesis, Exudation, and Degeneration 2025 meeting. The trial ...
Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDIA ® (finerenone) ...
Clinical Trials Arena on MSN
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial
The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.
Morning Overview on MSN
A 343-patient trial found a new drug combo extended survival in an aggressive brain cancer
People diagnosed with recurrent IDH-mutant grade 3 astrocytoma, a rare and aggressive brain cancer, lived roughly 11 months ...
LUGANO, Switzerland — Patients with diffuse large B-cell lymphoma (DLBCL) in a genetic subgroup associated with worse outcomes show significantly greater responses to treatment with the standard first ...
For Europe to remain an attractive site for phase 3 research, he argued, regulatory predictability is paramount. El-Galaly ...
Objective To assess the effect of calcium, vitamin D, or combined supplementation on fractures and falls in adults. Design Systematic review and meta-analysis. Data sources Trials included in ...
Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results